Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates-Reference-Cited by-同舟云学术

Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates

Published:2024-08-02 Issue: Volume: Page:
ISSN:1828-0447
Container-title:Internal and Emergency Medicine
language:en
Short-container-title:Intern Emerg Med

Author:

Casabella Andrea^ORCID,Paladin Francesca^ORCID,Bighin Claudia^ORCID,Ottaviani Silvia^ORCID,Marelli Cristina^ORCID,Ponzano Marta^ORCID,Signori Alessio^ORCID,Murdaca Giuseppe^ORCID,Cutolo Maurizio^ORCID,Molfetta Luigi^ORCID,Nencioni Alessio^ORCID,Paolino Sabrina^ORCID,Del Mastro Lucia^ORCID,Monacelli Fiammetta^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11739-024-03725-1.pdf

Reference24 articles.

1. Rahib L, Wehner MR, Matrisian LM, Nead KT (2021) Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 4(4):e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708

2. Lodi M et al (2017) Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat 166(3):657–668. https://doi.org/10.1007/s10549-017-4448-5

3. Eppenberger-Castori S et al (2002) Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34(11):1318–1330. https://doi.org/10.1016/s1357-2725(02)00052-3

4. Carli P et al (2012) Target therapy in elderly breast cancer patients. Crit Rev Oncol Hematol 83(3):422–431. https://doi.org/10.1016/j.critrevonc.2011.12.004

5. Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47(4):747–754. https://doi.org/10.1080/02841860802001467